Skip to content
Li Zhang MD; ESMO 2026: Bi-Specific Antibody-Drug Conjugate Doubles Progression Free Survival in Patients with NSCLC Progressing After Anti-EGFR TKI Therapy

Li Zhang MD; ESMO 2026: Bi-Specific Antibody-Drug Conjugate Doubles Progression Free Survival in Patients with NSCLC Progressing After Anti-EGFR TKI Therapy

Get the podcast

MADRID, Spain—Patients with EGFR-mutated advanced non-squamous non-small cell lung cancer progressing on third-generation EGFR tyrosine kinase inhibitors lived twice as long without progression when treated with the bispecific antibody-drug conjugate izalontamab brengitecan compared with patients in a control group who were treated with standard platinum-based chemotherapy. This was in the PANKU-Lung01 multicenter, randomized, open-label, phase 3 trial conducted in China and reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the study findings from senior author, Li Zhang MD, Medical Oncologist at Sun Yat-sen University Cancer Center in Guangzhou, China .

The Audio Journal of Oncology

Bi-Specific Antibody-Drug Conjugate Doubles Progression Free Survival in Patients with NSCLC Progressing After Anti-EGFR TKI Therapy

An interview with:

Li Zhang MD, Medical Oncologist, Sun Yat-sen University Cancer Center, Guangzhou, China

MADRID, Spain—Patients with EGFR-mutated advanced non-squamous non-small cell lung cancer progressing on third-generation EGFR tyrosine kinase inhibitors lived twice as long without progression when treated with the bispecific antibody-drug conjugate izalontamab brengitecan compared with patients in a control group who were treated with standard platinum-based chemotherapy.

This was in the PANKU-Lung01 multicenter, randomized, open-label, phase 3 trial conducted in China and reported at the 2026 Annual Congress of the European Society for Medical Oncology.

Peter Goodwin heard the latest on the study findings from senior author, Li Zhang MD, Medical Oncologist at Sun Yat-sen University Cancer Center in Guangzhou, China .

AUDIO JOURNAL OF ONCOLOGY: Li Zhang MD

SOURCE:

ESMO : LBA 71

Lancet, October 26, 2026

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02026-X/abstract

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China

Shaodong Hong, MDa,* ∙ Ting Zhou, MDa,* ∙ Xue Hou, MDa,* ∙ Prof Xiangjiao Meng, MDb,* ∙ Zhihuang Hu, MDc,* ∙ Prof Wei Zheng, MDd,* ∙ et al.

Background

Izalontamab brengitecan (iza-bren) is a first-in-class bispecific antibody–drug conjugate targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3) and has shown antitumour activity in EGFR-mutated non-small-cell lung cancer (NSCLC). We compared iza-bren with platinum-based chemotherapy in participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR tyrosine kinase inhibitors (TKIs).

Methods

In this multicentre, randomised, open-label, phase 3 trial (PANKU-Lung01) conducted at 73 sites in China, eligible participants had EGFR-mutated locally advanced or metastatic non-squamous NSCLC, disease progression after third-generation EGFR TKIs, and had received no previous chemotherapy for advanced disease. Participants were randomly assigned (1:1) to receive iza-bren (2·5 mg/kg intravenously on days 1 and 8 of each 3-week cycle) or pemetrexed plus carboplatin or cisplatin for four to six cycles, with pemetrexed maintenance permitted in participants without progression. The primary endpoint was progression-free survival assessed by blinded independent central review (BICR). The primary analysis included all randomly assigned participants who received at least one dose of study treatment (modified intention-to-treat population). We report the prespecified final progression-free survival and interim overall survival analyses. This trial is registered with ClinicalTrials.gov, NCT06382116.

Findings

Between May 22, 2024, and Sept 1, 2025, we screened 654 participants. After 222 (34%) were excluded, 432 (66%) participants were randomly assigned to iza-bren (n=217 [50%]) or chemotherapy (n=215 [50%]); 422 (98%) received study treatment (216 [51%] in the iza-bren group and 206 [49%] in the chemotherapy group) and comprised the modified intention-to-treat population.

At the data cutoff (July 15, 2026; median follow-up for progression-free survival 14·6 months [95% CI 12·9–16·7] in the iza-bren group vs 15·2 months [11·2–18·2] in the chemotherapy group), median BICR-assessed progression-free survival was 11·1 months (9·2–12·7) with iza-bren versus 5·7 months (5·5–5·9) with chemotherapy (hazard ratio [HR] 0·40 [95% CI 0·31–0·51]; one-sided p<0·0001). Treatment-related adverse events of grade 3 or worse occurred in 170 (79%) of 216 participants in the iza-bren group and 128 (62%) of 206 in the chemotherapy group (predominantly haematological); treatment-related adverse events led to permanent discontinuation of at least one study-treatment component in four (2%) participants in each group and treatment-related deaths occurred in one participant in each group. Treatment-related interstitial lung disease occurred in two (1%) participants in the iza-bren group and none in the chemotherapy group.

Interpretation

In participants with EGFR-mutated advanced non-squamous NSCLC after progression on third-generation EGFR TKIs, iza-bren significantly prolonged progression-free survival, although treatment-related adverse events of grade 3 or worse were more frequent than with chemotherapy. To our knowledge, these findings provide the first phase 3 evidence for a bispecific antibody–drug conjugate and support iza-bren as a potential treatment option in this population.

Li Zhang ESMO 2026 AJO Text

November 16, 2026

Next in ESMO 2006

All 2 interviews

Interview 2 of 2

Audio Journal of Oncology in Advance – November 1st, 2006

Audio Journal of Oncology in Advance – November 1st, 2006

David Cameron Martine Piccart Eric Van Cutsem Jim Cassidy Volker Heinemann Lapatinib Better for Patients with HER2+ Refractory Breast Cancer Pre-treated with Chemotherapy and Trastuzumab REFERENCE: ES

1 November 2006

Related Episodes

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

Jacob Sands MD; ESMO 2026: Tarlatamab Bispecific Antibody Maintenance Therapy Prolongs Life for Patients with Extensive Stage Small Cell Lung Cancer

MADRID, Spain—Patients with extensive stage small cell lung cancer now have the green-light to add treatment with the bispecific antibody tarlatamab to their maintenance anti-PD-1 immunotherapy after first line chemo-immunotherapy induction. Results from the phase 3 DeLLphi-305 trial were reported at the 2026 Annual Congress of the European Society for Medical Oncology showing significantly improved overall and progression-free survival. Peter Goodwin spoke with study author Jacob Sands MD, Associate Chief of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, in Boston, USA, and Assistant Professor of Medicine at Harvard Medical School:

12 Nov 2026
4 min
Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

Rebecca Dent MD; ESMO 2026: Dato-DXd Brings Dramatic CNS Responses to Patients with Brain Metastases from Resected Inoperable or Metastatic Triple Negative Breast Cancer

MADRID, Spain—The antibody-drug conjugate datopotamab deruxtecan (aTrop-2-directed antibody carrying a topoisomerase inhibitor payload) achieved clinically meaningful intracranial responses among patients with resected inoperable or metastatic triple negative breast cancer with CNS involvement in the TROPION-Breast02 study discussed at the 2026 Annual Meeting of the European Society for Medical Oncology. Peter Goodwin heard the details from the study’s first author: Rebecca Dent MD, Senior Consultant Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Centre in Singapore.

5 Nov 2026
10 min
James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

James Larkin PhD FRCP F Med Sci, ESMO 2026: Personalized mRNA Cancer Vaccines: Melanoma Study Success Provides Proof of Principle for Other Malignancies

MADRID, Spain— Personalized mRNA cancer vaccines for a range of tumor types are now seen as a realistic possibility thanks to mRNA technology already harnessed for treating melanoma in the phase III INTerpath-001 trial reported at the 2026 Annual Congress of the European Society for Medical Oncology. Peter Goodwin heard the latest on the potential of cancer vaccines from Scientific Co-Chair of ESMO 2026, James Larkin PhD FRCP F Med Sci, Head of The Royal Marsden Skin Unit, and Joint Training Programme Director for Medical Oncology and Lead of the Cancer Immunotherapy Theme at The Royal Marsden’s Institute of Cancer Research NIHR Biomedical Research Centre, in London UK.

2 Nov 2026
15 min